The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
Prostate Cancer
About this trial
This is an interventional treatment trial for Prostate Cancer focused on measuring Prostate Cancer
Eligibility Criteria
Main Inclusion Criteria: Patients, aged 18 years or over, with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated. Baseline testosterone >1.5 ng/mL. Life expectancy of at least 12 months.
Sites / Locations
- Urology Centers of Alabama
- Alaska Clinical Research Center, LLC
- Advanced Urology Medical Center
- Pacific Clinical Center
- Simi-San Faernando Valley Urology Associates
- South Orange County Medical Research Center
- Western Clinical Research
- Urology Associate PC
- University of Colorado
- South Florida Medical Research
- Florida Foundation for Healthcare Research
- Regional Urology
- Lawrenceville Urology
- Jay A. Motola, MD, FACS
- Northeast Urology Research
- The Urology Center
- State College Urologic Association
- Univeristy Urological Research Institute
- University Urological Research Institute
- Grand Strand Urology
- Urology San Antonio Research
- Urology of Virginia Research
- Office of Jeffrey Frankel
- Bruce W. Palmer Urology Inc, 125-70 Exhibition Street
- Nemocnice Jindrichuv Hradec a.s., U Nemocnice 380/III
- Urologische Klinik, Universitatsklinikum Mannheim, Theodor-Kutzer-Ufer 1-3
- Szeged M.J.V.O. Korhaza, Urologiai Osztaly, Kalvaria sugarut 57
- Hospital General "Dr Santiago Ramon y Cajal", ISSSTE
- Atrium MC, Henri Dunantstraat 5
- Cristo Redentor Hospital
- San Juan VA Medical Center
- Provita Center, 2 Primaverii Street
- Andros Urology Clinic, Ulitsa Lenina 36A
- Kiev City Clinical Hospital #3, Petr Ivaschenko 26, Petra Zaporogtsa str.
- Derriford Hospital, Derriford Road
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Active Comparator
degarelix 240/160 mg
degarelix 240/80 mg
Leuprolide 7.5 mg
Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.
Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.
Leuprolide (Lupron Depot) 7.5 mg IM (in the muscle) every 28 days starting at day 0.